Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | ACR | P10323 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11946638 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2TP53CYP4F2CYP4A11L3MBTL1 | |
| Methyl 3-Methoxybenzoate SCHEMBL29702092 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2TP53TSHRRAB9ANPC1 | |
| Methyl 3-Methoxybenzoate SCHEMBL384913 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2TP53TSHRRAB9ANPC1 | |
| SCHEMBL289656 | 0.83 | KMT2A (0.57) | SMN1; SMN2L3MBTL1RAB9ANPC1ALDH1A1 | |
| SCHEMBL2436534 | 0.83 | L3MBTL1 (0.65) | SMN1; SMN2TP53CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL521172 | 0.81 | SLC7A5 (0.48) | SMN1; SMN2TP53CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL177281 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53CYP4F2CYP4A11RAB9A | |
| SCHEMBL527464 | 0.81 | CYP4F2 (0.52) | SMN1; SMN2TP53CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL190231 | 0.81 | HDAC8 (0.56) | SMN1; SMN2TP53TSHRRAB9ANPC1 | |
| SCHEMBL25620305 | 0.81 | MEN1 (0.59) | SMN1; SMN2TP53L3MBTL1TSHRLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478792-B1 | CHEMILUMINESCENT SUBSTRATES | BECKMAN COULTER INC (US) | 2023-12-13 | — | — | EP | claimed |
| US-10703971-B2 | Chemiluminescent substrates | BECKMAN COULTER, INC. (US) | 2020-07-07 | — | — | US | claimed |
| US-20190161675-A1 | CHEMILUMINESCENT SUBSTRATES | BECKMAN COULTER, INC. (US) | 2019-05-30 | — | — | US | claimed |
| EP-3478792-A1 | CHEMILUMINESCENT SUBSTRATES | Beckman Coulter Inc. (US) | 2019-05-08 | — | — | EP | claimed |
| WO-2018006059-A1 | CHEMILUMINESCENT SUBSTRATES | BECKMAN COULTER, INC. (US) | 2018-01-04 | — | — | WO | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12545640-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-02-10 | — | — | US | disclosed |
| US-20260016471-A1 | IMPROVED ASSAY COMPOSITIONS AND METHODS | BECKMAN COULTER INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885TP53 503/4885CYP4F2 2014/4885 |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | SMN1; SMN2 21/4885TP53 4612/4885CYP4F2 3860/4885 |
| US-20260016471-A1 | IMPROVED ASSAY COMPOSITIONS AND METHODS | ALPL, AGL, ALPP | SMN1; SMN2 4616/4885TP53 729/4885CYP4F2 1401/4885 |
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | IKZF1, IKZF2, IKZF3 | SMN1; SMN2 2807/4885TP53 62/4885CYP4F2 59/4885 |
| US-12545640-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | ESRRA, GPER1, FSHR | SMN1; SMN2 3663/4885TP53 1751/4885CYP4F2 196/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | SMN1; SMN2 1231/4885TP53 242/4885CYP4F2 3600/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | SMN1; SMN2 4475/4885TP53 667/4885CYP4F2 2542/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | SMN1; SMN2 1645/4885TP53 3467/4885CYP4F2 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.